© 2018

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

  • Andrés J. M. Ferreri

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 17)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Mattias Mattsson, Lydia Scarfò
    Pages 1-22
  3. Mary Ann Anderson, Andrew W. Roberts, John F. Seymour
    Pages 23-43
  4. Kevin Barley, Samir Parekh
    Pages 45-71
  5. Teresa Calimeri, Andrés J. M. Ferreri
    Pages 85-105
  6. Back Matter
    Pages 135-138

About this book


In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. 


Lymphomas Malignancies Investigative trials Resistance Relapse

Editors and affiliations

  • Andrés J. M. Ferreri
    • 1
  1. 1.Department of Onco-HematologyUnit of Lymphoid Malignancies, IRCCS San Raffaele Scientific InstituteMilanItaly

About the editors

Andrés J. M. Ferreri has a degree in Medicine from the Facultad de Medicina of the Universidad de Buenos Aires, Argentina (1985), and obtained the degree of Doctor in Medicine and Surgery in the Facoltà di Medicina e Chirurgia dell’Università degli Studi di Parma, Italy, in 1992. He is a Specialist in Clinical Oncology (Università degli Studi di Milan, Italy, 2005). He was a research fellow at the Divisione di Oncologia Sperimentale “E” and at the Divisione di Oncologia Médica “A” of the Istituto Nazionale dei Tumori of Milan (1989–1994) and vice-director of the Medical Oncology Unit of the San Raffaele Scientific Institute of Milan, Italy. Currently, Dr. Ferreri is Head of the Unit of Lymphoid Malignancies of the San Raffaele Scientific Institute of Milan, and is a Contract Professor of Oncology in the Vita e Salute University, Milan. He is fully devoted to the research on non-Hodgkin lymphomas and is an opinion leader in the field of extranodal lymphomas. Dr. Ferreri is Associate Editor of the ESO/START Project and of “Haematological Oncology” and Faculty of the European School of Oncology. Dr. Ferreri is a member of EHA, ESMO, ASH, and ASCO.

Bibliographic information

  • Book Title Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
  • Editors Andrés J. M. Ferreri
  • Series Title Resistance to Targeted Anti-Cancer Therapeutics
  • Series Abbreviated Title Resistance to Targeted Anti-Cancer Therapeutics
  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-75183-2
  • Softcover ISBN 978-3-030-09165-1
  • eBook ISBN 978-3-319-75184-9
  • Series ISSN 2196-5501
  • Series E-ISSN 2196-551X
  • Edition Number 1
  • Number of Pages XIII, 138
  • Number of Illustrations 1 b/w illustrations, 13 illustrations in colour
  • Topics Cancer Research
    Molecular Medicine
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods